Abstract

Abstract Background Although consensus guidelines demonstrate clear benefit for the continuation of aspirin in patients awaiting coronary artery bypass grafting (CABG) following an acute coronary syndrome where risk of re-infarction outweighs bleeding risk, the evidence remains unclear in the case of elective CABG. We performed the largest to date systematic review and meta-analysis to compare outcomes between CABG patients who stopped and continued aspirin perioperatively. Methods A thorough search of PubMed, MEDLINE and CENTRAL databases was conducted to 25th July 2022 for randomized control trials that evaluated patients undergoing CABG. Summary odds ratios were calculated using a random effects model for dichotomous and continuous variables. Subgroup and sensitivity analyses were conducted in order to explore sources of heterogeneity. Results 16 eligible studies were included with a total of 6188 patients who underwent CABG. Patients who continued Aspirin perioperatively demonstrated an increased risk of all cause mortality [OR 1.37 (0.81-2.33)] and reduced risk of perioperative myocardial infarction [OR 0.81 (0.55-1.18)], however neither were statistically significant. No significant difference was observed between low-dose and higher doses of Aspirin. There was minimal heterogeneity amongst included studies (i2 = 0%, p=0.97 and i2=33%, p=0.13 respectively). Continuing aspirin produced a modest increase in postoperative blood loss [mean difference 66.12mL (-1.45-133.69)], as was a dose greater than 100mg [216.87(-152.99-586.72), p=0.60], however this was not statistically significant. Conclusion Continuing Aspirin before CABG is not associated with a significantly increased risk of all-cause mortality, of perioperative myocardial infarction, and of postoperative bleeding. Future trials with more robust methodology should be aimed at further evaluating this patient cohort to guide perioperative Aspirin use.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call